| 000 | 02653namuu22003371a 4500 | |
| 001 | 000045583368 | |
| 005 | 20100402134108 | |
| 008 | 100329s2009 fr a b i000 eng d | |
| 020 | ▼a 9789264076792 | |
| 020 | ▼a 9264076794 | |
| 040 | ▼a ERL ▼c ERL ▼d COD ▼d 211009 | |
| 082 | 0 4 | ▼a 338.476151 ▼2 22 |
| 090 | ▼a 338.476151 ▼b po | |
| 245 | 0 0 | ▼a Pharmacogenetics : ▼b opportunities and challenges for health innovation. |
| 246 | 3 0 | ▼a Opportunities and challenges for health innovation |
| 260 | ▼a Paris : ▼b OECD , ▼c c2009. | |
| 300 | ▼a 131 p. : ▼b col. ill ; ▼c 23 cm. | |
| 490 | 1 | ▼a OECD innovation strategy |
| 500 | ▼a "This work is published on the responsibility of the Secretary-General of the OECD"--T.p. verso. | |
| 500 | ▼a "The report was edited by Marilyn Smith and Lantz Miller"--Foreword. | |
| 504 | ▼a Includes bibliographical references | |
| 505 | 2 | ▼g Chapter 1. ▼t Introduction to the policy issues -- ▼g Chapter 2. ▼t The supporting infrastructures for pharmacogenetics -- ▼g Chapter 3. ▼t Pharmacogenetics and drug development -- ▼g Chapter 4. ▼t Business models for pharmacogenetics -- ▼g Chapter 5. ▼t Physician and patient demand for pharmacogenetics -- ▼g Chapter 6. ▼t Regulatory authorities and reimbursement mechanisms -- ▼g Chapter 7. ▼t Conclusions. |
| 520 | ▼a Pharmacogenetics helps us understand the relationship between an individual's genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimize the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training. -- Publisher's description. | |
| 650 | 0 | ▼a Pharmacogenetics |
| 650 | 0 | ▼a Pharmaceutical industry ▼x Technological innovations |
| 700 | 1 | ▼a Smith, Marilyn |
| 700 | 1 | ▼a Miller, Lantz |
| 710 | 2 | ▼a Organisation for Economic Co-operation and Development |
| 710 | 2 | ▼a OECD |
| 830 | 0 | ▼a OECD innovation strategy. |
소장정보
| No. | 소장처 | 청구기호 | 등록번호 | 도서상태 | 반납예정일 | 예약 | 서비스 |
|---|---|---|---|---|---|---|---|
| No. 1 | 소장처 학술정보관(CDL)/B1 국제기구자료실(OECD)/ | 청구기호 338.476151 po | 등록번호 181601905 | 도서상태 대출불가(자료실) | 반납예정일 | 예약 | 서비스 |
